Bio­gen cuts al­most one-third of Reata's staff fol­low­ing $7B buy­out

Bio­gen made a big M&A splash in Ju­ly with its $7.3 bil­lion buy­out of Rea­ta Phar­ma­ceu­ti­cals, which had just se­cured FDA ap­proval for a rare ge­net­ic dis­ease treat­ment. But now, as is the case with so many buy­outs, the Cam­bridge, MA-based biotech is cut­ting Rea­ta’s staff num­bers by al­most one-third.

Ac­cord­ing to a Texas no­tice post­ed this week, Rea­ta said it’s lay­ing off 113 staffers in No­vem­ber at a Plano, Texas, site, where Rea­ta has its head­quar­ters. As of Dec. 31, 2022, the com­pa­ny had 321 full-time em­ploy­ees.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER